Treatment overview of axial spondyloarthritis in 2023

Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101858. doi: 10.1016/j.berh.2023.101858. Epub 2023 Sep 5.

Abstract

The treatment of patients with axial spondyloarthritis (axSpA) is characterized by non-pharmacological and pharmacological treatment options. It may depend on the type and extent of musculoskeletal and extramusculoskeletal manifestations. Recent data on non-pharmacological treatment options, such as physical activity, physiotherapy, and modification of lifestyle factors, are summarized in this review. Moreover, we have provided an overview on non-steroidal anti-inflammatory drugs and the ever-expanding number of biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs, respectively). In addition to data on efficacy and safety, the review also encompasses data on switching/cycling, tapering, and treatment selection for specific patient subgroups to optimize treatment outcomes.

Keywords: Axial spondyloarthritis; Biological disease-modifying antirheumatic drugs; Interleukin-17 inhibitors; Janus kinase inhibitors; Treatment; Tumor necrosis factor inhibitors.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Axial Spondyloarthritis*
  • Humans
  • Spondylarthritis* / drug therapy
  • Spondylitis, Ankylosing* / drug therapy
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Anti-Inflammatory Agents, Non-Steroidal